1
|
Peters S, Besse B, Marreaud S, Dafni U, Oselin K, Havel L, Esteban Gonzalez E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Keller S, Mauer M, Jha N, Stahel R, Paz-Ares L, O'Brien M. 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Grégoire V, Tao Y, Kaanders J, Machiels J, Vulquin N, Nuyts S, Fortpied C, Lmalem H, Marreaud S, Overgaard J. OC-0278 Accelerated CH-RT with/without nimorazole for p16- HNSCC: the randomized DAHANCA 29-EORTC 1219 trial. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06828-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Schmoll H, Haustermans K, Price T, Nordlinger B, Hofheinz R, Daisne J, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig C, Zalcberg J, Tebbutt N, Mauer M, Marreaud S, Lutz M, Van Cutsem E. PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Bex A, Mulders P, Jewett M, Wagstaff J, Van Velthoven R, Laguna P, Wood L, Van Melick H, Soetekouw P, Lattouf J, Powles T, De Jong I, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME. ACTA ACUST UNITED AC 2018. [DOI: 10.1016/s1569-9056(18)30856-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
5
|
Touati N, Schoffski P, Litière S, Judson I, Sleijfer S, van der Graaf W, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marreaud S, Gronchi A. EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Casali P, Le Cesne A, Poveda A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson I, Italiano A, Gelderblom H, Penel N, Kopp HG, Goldstein D, Broto JM, Gronchi A, Wardelmann E, Marreaud S, Zalcberg J, Litière S, Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Bex A, Mulders P, Jewett M, Wagstaff J, van Velthoven R, Laguna Pes P, Wood L, van Melick H, Soetekouw P, Lattouf J, Powles T, Boleti E, de Jong IJ, Rottey S, Tombal B, Marreaud S, Collette L, Collette S, Blank C, Haanen J. Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.030] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Tryfonidis K, Marreaud S, Khaled H, De Valk B, Vermorken J, Welnicka-Jaskiewicz M, Aalders K, Bartlett JMS, Biganzoli L, Bogaerts J, Cameron D. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. Breast Cancer Res Treat 2017; 163:507-515. [PMID: 28324265 DOI: 10.1007/s10549-017-4203-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 03/13/2017] [Indexed: 11/28/2022]
Abstract
PURPOSE Cardiotoxicity is a side effect of trastuzumab. We assessed efficacy and cardiac safety of CMF with trastuzumab (CMF+T) in HER2-positive metastatic breast cancer patients (MBC). METHODS In this phase II study, centrally confirmed, previously treated HER2-positive MBC patients with measurable disease (per RECIST v 1.0) were enrolled. Initially, patients were randomized between 8 CMF cycles alone or combined with trastuzumab during chemotherapy, followed by 3-weekly trastuzumab maintenance till progression. A protocol amendment dropped the CMF arm and thereafter all patients received CMF+T. Translational research for prediction of treatment benefit was performed through serial serum HER2-shed antigen assessments. RESULTS Ninety patients (CMF: 19; CMF+T: 71) were enrolled between 2002 and 2006. Median age was 54 years. 42 patients had prior chemotherapy (33 with anthracyclines) and 41/71 patients who received CMF+T continued trastuzumab monotherapy for a median duration of 40 weeks. Overall response rate was 50% for CMF+T (35/70) and 32% for CMF (6/19). Median duration of response was 10.3 months and 5.4 months, respectively. Median progression-free survival was 9.4 months (95% CI 8.1-11.6) and 4.8 months (95% CI 2.8-7.9), respectively. In the CMF+T arm, 13(18%) patients had an absolute LVEF decline, including 3 patients developing any grade of New York Heart Association cardiac dysfunction. Patients with an increase of 30% over baseline shed antigen had a higher progression risk (95% CI 7.6, 3.9-14.8). CONCLUSIONS CMF+T is effective, with an acceptable cardiotoxicity profile. LVEF declines were mostly asymptomatic and occurred irrespective of previous anthracycline exposure. CMF+T can be considered for these patients, if other cytotoxics are contraindicated.
Collapse
Affiliation(s)
| | | | - H Khaled
- Department of Medical Oncology, National Cancer Institute- Cairo University, Cairo, Egypt
| | - B De Valk
- Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
| | - J Vermorken
- Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
| | - M Welnicka-Jaskiewicz
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - K Aalders
- EORTC Headquarters, Brussels, Belgium
| | - J M S Bartlett
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada.,University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK
| | - L Biganzoli
- Department of Medical Oncology, New Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
| | | | - David Cameron
- University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK.
| | | |
Collapse
|
9
|
Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 2017; 56:88-92. [PMID: 27838944 DOI: 10.1080/0284186x.2016.1234068] [Citation(s) in RCA: 122] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas. PATIENTS AND METHODS A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response was assessed according to RECIST 1.1. and survival analysis was performed. RESULTS Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS, respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS subtypes, respectively. There was no significant difference in response rate between cutaneous and non-cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median progression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three months (95% CI 2.1-4.4) and 9.9 months (95% CI 6.5-11.3) in AS, respectively. CONCLUSION The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.
Collapse
Affiliation(s)
- A. Kollár
- Sarcoma Unit, Department of Medical Oncology, University Hospital of Bern, Bern, Switzerland
| | - R. L. Jones
- Sarcoma Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | - S. Stacchiotti
- Sarcoma Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - H. Gelderblom
- Department of Medical Oncology, Leiden University Medical Center, RC Leiden, The Netherlands
| | - M. Guida
- Oncology Department, National Cancer Institute "Giovanni Paolo II", Bari, Italy
| | - G. Grignani
- Division of Medical Oncology, Candiolo Cancer Institue–FPO, IRCCS, Candiolo, Italy
| | - N. Steeghs
- Department of Medical Oncology, Pharmacology the Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - A. Safwat
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - D. Katz
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Kiryat Hadassah, Jerusalem, Israel
| | - F. Duffaud
- La Timone University Hospital & Aix-Marseille University (AMU), Marseille, France
| | - S. Sleijfer
- Department of Medical Oncology, Erasmus MC–Cancer Institute, Erasmus University Medical Center, CE Rotterdam, The Netherlands
| | - W. T. van der Graaf
- Sarcoma Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
- Department of Medical Oncology, Radboud University Medical Center, GA Nijmegen, The Netherlands
| | - N. Touati
- European Organization for Research and Treatment of Cancer (EORTC), Bruxelles, Belgium
| | - S. Litière
- European Organization for Research and Treatment of Cancer (EORTC), Bruxelles, Belgium
| | - S. Marreaud
- European Organization for Research and Treatment of Cancer (EORTC), Bruxelles, Belgium
| | - A. Gronchi
- Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - B. Kasper
- Sarcoma Unit, Interdisciplinary Tumor Center, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
10
|
Kollar A, Jones R, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van sder Graaf W, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw388.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Schmoll H, Stein A, Hofheinz R, Price T, Nordlinger B, Daisne JF, Daisne JF, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth F, Zalcberg J, Marreaud S, Mauer M, Lutz M, Van Cutsem E, Haustermans K. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: final analyses. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.16] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. Eur J Cancer 2015; 51:2615-23. [PMID: 26321011 DOI: 10.1016/j.ejca.2015.08.002] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Accepted: 08/06/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND Reliable biomarkers of pazopanib's efficacy in soft tissue sarcoma (STS) are lacking. Hypertension (HTN) is an on-target effect of vascular endothelial growth factor (VEGF)-receptor inhibitors such as pazopanib. We evaluated the association of pazopanib-induced HTN with antitumour efficacy in patients with metastatic non-adipocytic STS. METHODS Associations between pazopanib-induced-HTN and antitumour efficacy were retrospectively assessed across 2 prospective studies (European Organisation for Research and Treatment of Cancer (EORTC) study 62043 and 62072) in metastatic STS patients who received pazopanib 800 mg daily. Only patients with baseline blood pressure (BP)<150/90 mmHg, were included. BP was measured monthly. HTN was reported according to National Cancer Institute-Common Toxicity Criteria Adverse Events (NCI-CTC AE) grading (v3.0), and as absolute differences compared to baseline. The effect of HTN developing in patients without baseline anti-hypertensive medication was assessed on progression-free (PFS) and overall survival (OS) using a landmark analysis stratified by study; univariately using the Kaplan-Meier method and a log-rank test, and in a multivariate Cox regression model after adjustment for important prognostic factors. RESULTS Of the 337 patients eligible for this analysis, 21.7% received anti-hypertensive medication at baseline and had a similar PFS and OS compared to those who did not. In patients without baseline anti-hypertensive medication, 38.6% developed HTN. As the majority of patients developing HTN did so within 5 weeks after initiation of pazopanib (68.6%), this time point was used as landmark. Univariately, there was no effect on PFS or OS from occurrence of HTN within 5 weeks of treatment expressed either in NCI-CTC AE criteria or as maximal differences from baseline in systolic and diastolic BP. Also in multivariate analysis, after adjusting for important prognostic factors, the occurrence of HTN expressed in the different parameters was not associated with PFS and OS. CONCLUSIONS In this retrospective analysis, pazopanib-induced HTN did not correlate with outcome in pazopanib-treated STS patients. The occurrence of HTN cannot serve as biomarker in this setting.
Collapse
Affiliation(s)
- F Duffaud
- La Timone University Hospital & Aix-Marseille University (AMU), Marseilles, France.
| | - S Sleijfer
- Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands
| | - S Litière
- EORTC Headquarters, Brussels, Belgium
| | - I Ray-Coquard
- Centre Leon Bérard & University Lyon I, Lyon, France
| | - A Le Cesne
- Institut Gustave Roussy, Villejuif, France
| | - Z Papai
- Military Hospital - State Health Centre, Budapest, Hungary
| | - I Judson
- Royal Marsden Hospital, London, UK
| | - P Schöffski
- Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospitals, Leuven, Belgium
| | - S P Chawla
- Sarcoma Oncology center, Santa Monica, CA, USA
| | - R Dewji
- GlaxoSmithKline - Oncology R&D, Uxbridge, UK
| | | | - J Verweij
- Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands
| | | |
Collapse
|
13
|
Le Cesne A, Ouali M, Leahy M, Santoro A, Hoekstra H, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward W, Gronchi A, Hogendoorn P, Litiere S, Marreaud S, Blay J, Van Der Graaf W. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol 2014; 25:2425-2432. [DOI: 10.1093/annonc/mdu460] [Citation(s) in RCA: 114] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
van der Graaf W, Le Cesne A, Mir O, Gelderblom H, Italiano A, Marreaud S, Judson I, Litiere S. Outcome of First-Line Treatment of Elderly Advanced Soft Tissue Sarcoma (Sts) Patients: a Pooled Analysis of Eleven Eortc Soft Tissue and Bone Sarcoma Group Trials. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu354.4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Kasper B, Sleijfer S, Litière S, Marreaud S, Verweij J, Hodge RA, Bauer S, Kerst JM, van der Graaf WTA. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 2014; 25:719-724. [PMID: 24504442 PMCID: PMC4433518 DOI: 10.1093/annonc/mdt586] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Revised: 11/04/2013] [Accepted: 12/02/2013] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Pazopanib recently received approval for the treatment of certain soft tissue sarcoma (STS) subtypes. We conducted a retrospective analysis on pooled data from two EORTC trials on pazopanib in STS in order to characterize long-term responders and survivors. PATIENTS AND METHODS Selected patients were treated with pazopanib in phase II (n = 118) and phase III study (PALETTE) (n = 226). Combined median progression-free survival (PFS) was 4.4 months; the median overall survival (OS) was 11.7 months. Thirty-six percent of patients had a PFS ≥ 6 months and were defined as long-term responders; 34% of patients survived ≥18 months, defined as long-term survivors. Patient characteristics were studied for their association with long-term outcomes. RESULTS The median follow-up was 2.3 years. Patient characteristics were compared among four subgroups based on short-/long-term PFS and OS, respectively. Seventy-six patients (22.1%) were both long-term responders and long-term survivors. The analysis confirmed the importance of known prognostic factors in metastatic STS patients treated with systemic treatment, such as performance status and tumor grading, and additionally hemoglobin at baseline as new prognostic factor. We identified 12 patients (3.5%) remaining on pazopanib for more than 2 years: nine aged younger than 50 years, nine females, four with smooth muscle tumors and nine with low or intermediate grade tumors at initial diagnosis. The median time on pazopanib in these patients was 2.4 years with the longest duration of 3.7 years. CONCLUSIONS Thirty-six percent and 34% of all STS patients who received pazopanib in these studies had a long PFS and/or OS, respectively. For more than 2 years, 3.5% of patients remained progression free under pazopanib. Good performance status, low/intermediate grade of the primary tumor and a normal hemoglobin level at baseline were advantageous for long-term outcome. NCT00297258 (phase II) and NCT00753688 (phase III, PALETTE).
Collapse
Affiliation(s)
- B Kasper
- Interdisciplinary Tumor Center, Sarcoma Unit, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany.
| | - S Sleijfer
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - S Litière
- EORTC Data Centre, Brussels, Belgium
| | | | - J Verweij
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - R A Hodge
- Oncology TA Group, GlaxoSmithKline, Uxbridge, UK
| | - S Bauer
- Sarcoma Center, West German Cancer Center, Essen, Germany
| | - J M Kerst
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam
| | - W T A van der Graaf
- Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands
| |
Collapse
|
16
|
Gelderblom H, Blay J, Seddon B, Leahy M, Ray-Coquard I, Sleijfer S, Kerst J, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten R, Guchelaar HJ, Weitman S, Hogendoorn P, Hohenberger P. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. Eur J Cancer 2014; 50:388-96. [DOI: 10.1016/j.ejca.2013.10.002] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2013] [Revised: 09/26/2013] [Accepted: 10/03/2013] [Indexed: 11/29/2022]
|
17
|
Bonnefoi H, Zaman K, Debled M, Fiche M, Fournier M, Nobahar M, Pierga JY, Koch KM, Bartlett J, Zimmer A, Marreaud S, Bogaerts J, Cameron D. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer. Eur J Cancer 2012; 49:281-9. [PMID: 22999386 DOI: 10.1016/j.ejca.2012.08.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Revised: 08/03/2012] [Accepted: 08/06/2012] [Indexed: 10/27/2022]
Abstract
BACKGROUND Lapatinib is an effective anti-HER2 therapy in advanced breast cancer and docetaxel is one of the most active agents in breast cancer. Combining these agents in pre-treated patients with metastatic disease had previously proved challenging, so the primary objective of this study aimed to determine the maximum tolerated dose (MTD) in treatment-naive patients, by identifying acute dose-limiting toxicities (DLT) during cycle 1 in the first part of a phases 1-2 neoadjuvant European Organisation for Research and Treatment of Cancer (EORTC) trial. PATIENTS AND METHODS Patients with large operable or locally-advanced HER2 positive breast cancer were treated with continuous lapatinib, and docetaxel every 21days for 4 cycles. Dose levels (DLs) were: 1000/75, 1250/75, 1000/85, 1250/85, 1000/100 and 1250/100 (mg/day)/(mg/m(2)). RESULTS Twenty-one patients were included. Two DLTs occurred at dose level 5 (1000/100); one grade 4 neutropenia ≥ 7days and one febrile neutropenia. A further 3 patients were therefore treated at the same dose with prophylactic granulocyte-colony stimulating factor (G-CSF), and 3 patients at dose level 6. No further DLTs were observed. CONCLUSIONS Our recommended dose for phase II is lapatinib 1000mg/day and docetaxel 100mg/m(2) with G-CSF in HER2 positive non-metastatic breast cancer. The dose of lapatinib should have been 1250mg/day but we were mindful of the high rate of treatment discontinuation in GeparQuinto with lapatinib 1250mg/day combined with docetaxel. No grade 3-4 diarrhoea was observed. Pharmacodynamics analysis suggests that concomitant medications altering P-glycoprotein activity (in addition to lapatinib) can modify toxicity, including non-haematological toxicities. This needs verification in larger trials, where it may contribute to understanding the sources of variability in clinical toxicity and treatment discontinuation.
Collapse
Affiliation(s)
- H Bonnefoi
- Institut Bergonié, INSERM U916, Bordeaux, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Van der Graaf W, Blay J, Chawla S, Kim D, Bui-Nguyen B, Van Glabbeke M, Marreaud S, Pandite L, Dei Tos P, berger PH. 9400 ORAL Prognostic and Predictive Factors in Advanced Soft Tissue Sarcoma Patients Treated in an EORTC STBSG Global Network Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo (EORTC 62072, PALETTE). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72544-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
19
|
Van Der Graaf WT, Blay J, Chawla SP, Kim D, Bui Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji M, Dei Tos AP, Hohenberger P. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.lba10002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA10002 Background: Pazopanib, a multi targeted angiogenesis inhibitor, has demonstrated single-agent activity in pts with advanced STS. The efficacy and safety of pazopanib versus placebo as second or later line treatment were evaluated in pts with metastatic STS in a multi-center, international, double-blind, placebo-controlled phase III trial. Methods: Pts ≥18 years of age with angiogenesis inhibitor-naïve, histologically proven, metastatic STS, who failed at least one anthracycline containing regimen, could enter the study. They should have ≥1 measurable baseline lesion (per RECIST v1.0), WHO PS 0-1, adequate bone marrow, coagulation, hepatic and renal function, no poorly controlled hypertension, no bleeding diathesis, and no CNS involvement. The study has been conducted by EORTC and GSK in collaboration with 72 sarcoma centers worldwide. Pts were randomized 2:1 to receive either pazopanib 800 mg once daily or placebo until tumor progression, unacceptable toxicity, death, or pt’s request. Results: A total of 369 randomized pts (246 pazopanib, 123 placebo), median age of 56 years, participated in the study (EORTC 45 %, other 55%). Median duration of follow-up at clinical cut-off date is 15 months. The primary endpoint of progression-free survival (PFS) per independent review is significantly prolonged with pazopanib (median: 20 vs 7 weeks; HR=0.31, 95% CI 0.24-0.40 ; P<0.0001). The interim analysis for overall survival shows a statistically non-significant improvement of pazopanib vs placebo (median: 11.9 vs 10.4 months, HR=0.83, 95% CI 0.62-1.09). Main on-therapy grade 3-4 toxicities in the pazopanib vs placebo arm respectively: fatigue (13%, 6%), hypertension (7%, nil), anorexia (6%, nil), and diarrhea (5%, 1%). Similarly, thromboembolic events (grade 3-5 ) (3%, 2%), LVEF drop of >15% (8%, 3%). Median relative dose intensity of pazopanib was 768 mg daily. Conclusions: Pazopanib is an active drug in anthracycline pretreated metastatic STS pts with an increase in median PFS of 13 weeks.
Collapse
Affiliation(s)
- W. T. Van Der Graaf
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - J. Blay
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - S. P. Chawla
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - D. Kim
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - B. Bui Nguyen
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. G. Casali
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. Schöffski
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Aglietta
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. P. Staddon
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - Y. Beppu
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. Le Cesne
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - H. Gelderblom
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - I. R. Judson
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - N. Araki
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Ouali
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - S. Marreaud
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - R. Hodge
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Dewji
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. P. Dei Tos
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. Hohenberger
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| |
Collapse
|
20
|
Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay J, Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2011; 22:1266-1272. [DOI: 10.1093/annonc/mdq608] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
De Wit R, Skoneczna IA, Gedske Daugaard K, de Santis M, Garin A, Aass N, Witjes JA, Albers P, White J, Germa-Lluch JR, Osanto S, Marreaud S, Collette L. A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4509] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Penel N, Van Glabbeke MM, Bui Nguyen B, Ouali M, Mathoulin-Pelissier S, Marreaud S, Italiano A, Brouste V, Hogendoorn PCW, Coindre J, Blay J, Hohenberger P. Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Van Der Graaf WT, Blay J, Chawla SP, Kim D, Bui Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji M, Dei Tos AP, Hohenberger P. PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.lba10002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2010; 22:1054-1061. [PMID: 21059637 DOI: 10.1093/annonc/mdq575] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell infusion [high-dose chemotherapy (HD-CT arm)] to four cycles of standard cisplatin, etoposide, and bleomycin (BEP) in patients with poor-prognosis germ-cell cancer (GCC). PATIENT AND METHODS Patients with poor-prognosis GCC were assigned to receive either BEP or VIP followed by HD-CT. To show a 15% improvement in a 1-year failure-free survival (FFS), the study aimed to recruit 222 patients but closed with 137, due to slow accrual. RESULTS One hundred thirty-one patients were included in this analysis. The complete response rates in the HD-CT and in the BEP arm did not differ: (intention to treat) 44.6% versus 33.3% (P = 0.18). There was no difference in FFS between the two treatment arms (P = 0.057, 66 events). At 2 years, the FFS rate was 44.8% [95% confidence interval (CI) 32.5-56.4] and 58.2%, respectively (95% CI 48.0-71.9); but this 16.3% (standard deviation 7.5%) difference was not statistically significant (P = 0.060). Overall survival did not differ between the two groups (log-rank P > 0.1, 47 deaths). CONCLUSION This study could not demonstrate that high-dose chemotherapy given as part of first-line therapy improves outcome in patients with poor-prognosis GCC.
Collapse
Affiliation(s)
- G Daugaard
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
| | - I Skoneczna
- Department of Urology, Chemotherapy Unit, Maria Sklodowska-Curie Memorial Center, Warsaw, Poland
| | - N Aass
- Department of Oncology, Oslo University Hospital and University of Oslo, Oslo, Norway
| | - R De Wit
- Department Medical Oncology, Erasmus University Hospital, Rotterdam, The Netherlands
| | - M De Santis
- LBI-ACR VIEnna and ACR-ITR VIEnna/CEADDP-Kaiser Franz Josef-Spital, Vienna, Austria
| | - H Dumez
- Department of Oncology, University Hospitals, Leuven, Belgium
| | - S Marreaud
- European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
| | - L Collette
- European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
| | - J R G Lluch
- Institut Català d'Oncologia, Htal. Duran i Reynals, Hòspitalet Barcelona, Barcelona, Spain
| | - C Bokemeyer
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Cancer Center (UCCH), University Medical Center Hamburg Eppendorf, Hamburg
| | - H J Schmoll
- Department of Oncology and Hematology, Martin Luther University, Halle, Germany
| |
Collapse
|
25
|
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy MG, Daugaard G, Gil T, Maroto JP, Marreaud S, Sylvester R. Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.18_suppl.lba4519] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA4519 Background: About 50% of pts with advanced UC are not eligible for cisplatin based CHT (“unfit”) due to impaired renal function, performance status (PS) or comorbidity. This is the first randomized phase II/III trial comparing two chemotherapy regimens in this pts group. Methods: The primary objective of the phase III part of this study was to compare the overall survival (OS) of CHT naïve pts with measurable disease and an impaired renal function (GFR<60 but >30 ml/min) and/or PS 2 who were randomized to receive either GC (G 1000 mg/m2 d1 and 8 and C AUC 4.5) q21 days or M-CAVI (M 30 mg/m2 d1 and 15 and 22, C AUC 4.5 d1 and VI 3 mg/m2 d1 and 15 and 22) q28 days. In order to detect an increase of 50% in median survival on GC compared to M-CAVI (13.5 versus 9 months) based on a two sided logrank test at error rates alpha=0.05 and beta=0.20, 225 pts were required. Secondary endpoints were overall response rate (ORR) and progression free survival (PFS). Results: 238 pts, 119 in each arm, were randomized between January 2001 and March 2008 by 29 institutions. The median follow-up is 4.5 years. Two pts were ineligible and two other pts never started treatment. Best ORRs (CR + PR) were 41.2% (36.1% confirmed response) on GC versus 30.3% (21.0% confirmed response) on M-CAVI (p = 0.08). Median OS was 9.3 months on GC and 8.1 months on M-CAVI (p = 0.64). There was no difference in PFS between the two arms (p = 0.78). OS, PFS and ORR were similar in each of the risk groups (reason unfit for cisplatin and Bajorin risk group). Severe acute toxicity (SAT) (death, grade 4 thrombocytopenia with bleeding, or grade 3/4 renal toxicity, neutropenic fever or mucositis) was observed in 9.3% of pts on GC (2 toxic deaths) and 21.2% on M-CAVI (4 toxic deaths). The most common grade 3/4 toxicities were leucopenia (44.9%, 46.6%), neutropenia (52.5%, 63.5%), febrile neutropenia (4.2%, 14.4%), thrombocytopenia (48.3%, 19.4%), and infection (11.8%, 12.7%) on GC and M-CAVI, respectively. Conclusions: There were no significant differences in efficacy between the two treatment groups. The incidence of SATs was slightly higher on M-CAVI. [Table: see text]
Collapse
Affiliation(s)
- M. De Santis
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - J. Bellmunt
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - G. Mead
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - J. M. Kerst
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - M. G. Leahy
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - G. Daugaard
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - T. Gil
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - J. P. Maroto
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - S. Marreaud
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| | - R. Sylvester
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria; Hospital del Mar, IMIM, Barcelona, Spain; Royal South Hants Hospital, Southhampton, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; St. James Hospital, Leeds, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Institut Jules Bordet, Brussels, Belgium; Hospital Santa Creu, Barcelona, Spain; EORTC Headquarters, Brussels, Belgium
| |
Collapse
|
26
|
Daugaard G, Skoneczna IA, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Bokemeyer C, Schmoll H. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4512] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Sleijfer S, Van Glabbeke MM, Lamers C, Burger H, Blay J, Cesne AL, Scurr MR, Bartlett-Pandite AN, Marreaud S, Hohenberger P. Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): An EORTC-STBSG study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Cameron DA, Marreaud S, Zaman K, Bodmer A, Pierga J, Brain E, Veyret C, Bartlett JM, Bogaerts J, Bonnefoi HR. LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neoadjuvant therapy of HER2-positive breast cancer—EORTC 10054 trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Van Laarhoven H, Desar I, Asten J, Fiedler WM, Marreaud S, Timmer-Bonte JN, Teroert E, Bordignon C, Heerschap A, Van Herpen C. Vascular effects of the vascular targeting agent NGR-hTNF in patients (pts) with advanced solid cancer: A dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) EORTC study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Bonnefoi H, Zaman K, Nobaher M, Brain E, Pierga J, Koch K, Bartlett J, Marreaud S, Bogaerts J, Cameron D. 5073 Lapatax: Safety profile of neoadjuvant lapatinib combined with docetaxel in Her 2/neu overexpressing breast cancer – EORTC protocol 10054. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70965-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
31
|
van Laarhoven H, Fiedler W, Desar IM, van Asten S, Marreaud S, Belli R, Bordignon C, Heerschap A, Punt CJ, van Herpen CM. Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3521] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
De Santis M, Bellmunt Molins J, de Wit R, Mead B, Kerst JM, Leahy M, Maroto P, Skoneczna IA, Marreaud S, Sylvester RJ. Randomized phase II/III trial assessing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) “unfit” for cisplatin based chemotherapy (CHT): Updated phase II results and risk group analysis of EORTC study 30986. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Heerschap A, Fiedler W, Marreaud S, van Laarhoven H, Govaerts A, Peters M, Toma S, Bordignon C, Punt K, Van Herpen C. A phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14074 Background: NGR-TNF is a novel agent exploiting a tumour homing peptide (cNGRCG) that selectively targets CD13 that is expressed on the neovasculature of solid tumors. Preclinical data show that its antitumour activity is achieved by a change of vascular permeability (at low doses) and damage of tumour-associated blood vessels (at high doses). This phase I study is being conducted to assess its safety, PK, PD, MTD, and optimal biological dose in patients (pts) with advanced solid tumours. Methods: NGR-TNF was administered once every 3 weeks by a 20 min IV infusion to cohorts of 3–6 pts. The starting dose was 0.2 μg/m2. Dose escalation was performed with a doubling of the dose until grade 2 toxicity was observed; thereafter a modified Fibonacci schedule was used. PK and PD analysis in blood was performed during the first 4 cycles. DCE-MRI was performed in cycle 1 at baseline and 2 hours after start of the infusion to document modification of the tumour vascularity. Anti-tumour activity was assessed by CT scan every 2 cycles. Results: 45 pts were treated and 133 cycles of treatment completed up to now. 12 DLs have been visited (0.2 to 14.36 μg/m2). One DLT (bronchospasm G 3) was observed at DL4 (1.3 μg/m2) and the DL was extended to 7 pts. As no other DLT was observed, dose escalation was continued. Since then no additional pt experienced dose-limiting toxicity. As 3/18 first pts experienced chills G 2 during injection time, the study was amended and infusion time increased to 1 hour. Since then 1/14 next pts had G 2 chills. Overall most frequently related adverse events reported in the first 34 pts: chills 76%, fever 44%, nausea 20%, constipation 12%, diarrhea 9%, anorexia and hypotension 6%. PK/PD analysis for the plasma levels of TNF-RI and TNF-RII showed a better profile for the 60 min compared with the 20 min infusion. At DL = 1.3 μg/m2 most pts showed a decrease in kep and the number of pixels with a low fraction of kep and Ktrans significantly increased (p<0.05), as seen with other anti- vascular agents. Stable disease was observed in 39% of pts, with a median duration of 11 wks (range 5–36). No responses were observed. Conclusions: NGR-hTNF is well tolerated and some biological activity was observed by DCE-MRI. Study enrollment is ongoing. [Table: see text]
Collapse
Affiliation(s)
- A. Heerschap
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - W. Fiedler
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - S. Marreaud
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - H. van Laarhoven
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - A. Govaerts
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - M. Peters
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - S. Toma
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - C. Bordignon
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - K. Punt
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| | - C. Van Herpen
- Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Universitaets-Krankenhaus Eppendorf, Hamburg, Germany; EORTC, Brussels, Belgium; MolMed, Milan, Italy
| |
Collapse
|
34
|
Neskovic-Konstantinovic Z, Nooij M, Khaled H, De Valk B, Vermorken J, Welnicka-Jaskiewicz M, Piccart M, Marreaud S, Bogaerts J, Cameron D. Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1040 Background: Safety and efficacy of classical CMF combined with 3-weekly Trastuzumab (T), followed by T alone in metastatic breast cancer (MBC). Methods: Patients (pts) with previously treated MBC were enrolled into a Phase II study of T (4 mg/kg then by 2 mg/kg) IV weekly plus CMF, Bonadonna regimen, for a maximum of 8 cycles (cy), followed by T alone (6 mg/kg) IV 3 weekly. Entry criteria included HER2 overexpression, limited anthracycline (A) exposure, normal baseline LVEF and measurable disease (RECIST). Cardiac endpoints were defined as: symptomatic CHF or LVEF drop by ≥ 15% from baseline or to ≥ 5% below lower limit. Results: The trial was closed to recruitment in January 2006, 12 pts are still on treatment. Seventy one pts were entered with a median age of 54 (range 31–75). Forty-one pts had prior CT (32 A), of which 26 adjuvant, 6 MBC, and 9 both adjuvant and MBC. Median PS was 0, 52 pts had visceral disease with a median interval from diagnosis to first relapse of 33.4 months (mo). Out of 70 pts receiving T+CMF (33 pts with 8 cy), 42 continued with T alone for a median duration of 7 cy. Eleven pts discontinued treatment for toxicity (9 on T+CMF, 2 on T alone). To date, the overall response rate is 55% (31/56 pts): 55% (23/42) 1st line; 57% (8/14) 2nd line. An independent review of responses is on-going. Median time to response was 2 mo, median duration of response was 8.3 mo and the median progression free survival was 9.2 mo. The most common grade 3–4 toxicity was neutropenia (53 %). Fourteen pts had cardiac toxicities, one NYHA grade 2 CHF, 6 pts with a drop in LVEF of 15% from baseline after a median of 3 mo of treatment, 9 pts with a drop in LVEF of 5% below LLN, after a median of 8 mo of treatment. The other toxicities included one grade 3 arrhythmia, two grade 3 hypertension, one grade 2 SVT, one grade 3 thrombosis, and one grade 2 dyspnea. One pt previously exposed to A had NYHA grade 4 CHF one year after treatment discontinuation. Conclusions: Combination of T+CMF regimen is feasible treatment for HER2+ MBC patients. The safety profile was acceptable, with cardiac toxicity and neutropenia within previously reported range. Drops in LVEF were mostly asymptomatic irrespective of previous exposure to A. Preliminary response data confirm good efficacy of CMF+T in MBC patients. [Table: see text]
Collapse
Affiliation(s)
- Z. Neskovic-Konstantinovic
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - M. Nooij
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - H. Khaled
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - B. De Valk
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - J. Vermorken
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - M. Welnicka-Jaskiewicz
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - M. Piccart
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - S. Marreaud
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - J. Bogaerts
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - D. Cameron
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| |
Collapse
|
35
|
Garufi C, Focan C, Tumolo S, Coudert B, Iacobelli S, Tubiana N, Marreaud S, Lentz M, Gorlia T, Lévi F. Time finding study of chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L) and oxaliplatin (O) (chronoIFLO) against metastatic colorectal cancer: Results from randomized EORTC 05011 trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2566 Background: We previously showed that a) irinotecan (I) could be combined with chronoFLO in MMC patients; b) least toxic times (LTT) for combined I and oxaliplatin respectively correspond to the middle of the rest-phase and the middle of acivity-phase in tumor-bearing mice; c) chrono I showed adequate activity in a randomized phase II trial; and d) MMC resistance can be partly overcome with chronoIFL. Methods: The objective was to identify the LTT for I characterized by a minimal dose reduction/delay among the first 3 courses (c). Assuming that the toxic effect of I had a 24-h periodicity patients were randomized in 6 groups with I peak delivery (180 mg/m2, 6-h sinusoidal infusion on day 1) at 1:00, 5:00, 9:00 am, 1:00, 5:00, or 9:00 pm. . All the groups received also chronoFLO on days 2–5, q 3 weeks (F 700 mg/m2/d & L 150 mg/m2/d; from 22:15 to 9:45 with peak delivery at 4:00 , O 20 mg/m2/d from 10:15 to 21:45, with peak delivery at 16:00). Based on a logistic regression model, a 15% reduction in toxic events in the first 3 c, 186 patients were considered necessary to estimate the LTT with a 95% CI (calculated by bootsrap) of less than 6 h. Results: 197 of 199 randomized MMC patients were considered for tolerability and safety with median age 61 years (30–81), sex (M 68% - F 32%) and PS (0/1/2 73/23/4%); therapy was 1st line in 77 patients and 2nd line in 23%. Thithy-one percent of severe protocol violations occurred, 16% of pump malfunctions (>10% dose delivery deviation). Median number of c was 6 (1–18). There were 3 toxic deaths. The observed LTT for I tolerability was 3:15 am (95 CI: 3:40–1:50 pm, NS). Grade 3–4 diarrhea ranged from 34 to 51.6% with LTT at 1:53 pm (4:29 -2:53 am, not significant, NS); neutropenia from 9 to 25% with LTT at 3:26 pm (10:50 - 4:55 am, NS). Age was a negative prognostic factor for diarrhea (p =0.01). Conclusion: This trial failed to show a statistically significant LTT for this combination in MCC patients. The safety profile of I combined with ChronoIFLO was acceptable, with diarrhea and neutropenia within previously reported range. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Garufi
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - C. Focan
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - S. Tumolo
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - B. Coudert
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - S. Iacobelli
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - N. Tubiana
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - S. Marreaud
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - M. Lentz
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - T. Gorlia
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - F. Lévi
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| |
Collapse
|
36
|
Sleijfer S, Papai Z, Le Cesne A, Scurr M, Ray-Coquard I, Collin F, Pandite L, Marreaud S, De Brauwer A, Blay J. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10031] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10031 Background: Currently, there is no standard treatment for pts with advanced STS who relapse after or during standard chemotherapy. Since VEGF is involved in the pathogenesis of STS subtypes, pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGF- receptors 1–3, PDGFR-a and β, and c-kit was explored. Methods: Pts had intermediate or high grade advanced or metastatic STS, were ineligible for chemotherapy or had received no more than one combination or 2 single cytotoxic agents for advanced disease. Pts had WHO performance 0–1 and adequate organ function. Progressive disease had to be documented within the last 6 months. Treatment was oral pazopanib at 800 mg daily. Primary end point was progression-free survival at 12 weeks. Secondary end points included response, safety, and overall survival. 4 different strata were studied: leiomyosarcomas, adipocytic STS, synovial sarcomas, and other types of STS. Simon 2-stage design was applied (P1: 40%; P0: 20%; a=β=0.1). Results: As of 11 October, 2006, 111 pts were enrolled. 98.2% had received prior chemotherapy. In 44 pts with validated data no grade 3–4 hematological toxicities were seen, grade 3–4 bilirubin and creatinine elevations in 2 and 1 pts, respectively. Other toxicities (all grades; grade 3–4) were fatigue (53.6%; 9.7%), hypertension (31.7%; 9.7%), and diarrhea (29.3%; 4.8%). Of 80 pts included in the 1st stages of all 4 strata together, 27 were alive and progression-free at 12 weeks. The 2nd stage was opened for further accrual in 3 strata. Complete accrual is anticipated in February 2007. Conclusions: In relapsed or refractory advanced STS, pazopanib has acceptable toxicity. These preliminary results justify further investigation of pazopanib in STS. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Sleijfer
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - Z. Papai
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - A. Le Cesne
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - M. Scurr
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - I. Ray-Coquard
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - F. Collin
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - L. Pandite
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - S. Marreaud
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - A. De Brauwer
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| | - J. Blay
- Erasmus Medical Center, Rotterdam, The Netherlands; National Medical Center, Budapest, Hungary; Institue Gustave Roussy, Villejuif, France; Royal Marsden Hospital, London, United Kingdom; Centre Leon Berard, Lyon, France; Centre Georges-Francois Leclerc, Dijon, France; GlaxoSmithKline, Research Triangle Park, NC; EORTC, Brussels, Belgium
| |
Collapse
|
37
|
Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2007; 61:579-85. [PMID: 17520255 DOI: 10.1007/s00280-007-0509-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2007] [Accepted: 04/22/2007] [Indexed: 10/23/2022]
Abstract
PURPOSE OSI-7904L is a liposomal formulation of a potent thymidylate synthase (TS) inhibitor. This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma. METHOD A 3+3 study design was utilized at predefined dose levels. Polymorphisms in the TS enhancer region and XPD enzyme were investigated as potential predictors of efficacy and toxicity. RESULTS Fourteen patients received 76 cycles of treatment. At the highest dose level (OSI-7904L 9 mg/m(2), oxaliplatin 130 mg/m(2)) investigated, one of nine patients experienced dose-limiting toxicity of grade 3 oral mucositis with cycle 1 and five further patients required dose reductions. The toxicity profile of stomatitis, diarrhea, nausea, fatigue, sensory neuropathy and skin rash was consistent with that expected for a TS inhibitor/oxaliplatin combination regimen. PK analysis showed high interpatient variability with no detectable interaction between OSI-7904L and oxaliplatin. Partial radiological responses were documented in two patients. CONCLUSIONS The recommended regimen for further investigation is OSI-7904L 9 mg/m(2) and oxaliplatin 130 mg/m(2).
Collapse
Affiliation(s)
- A R Clamp
- Cancer Research UK and University of Manchester Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Reichardt P, Nielsen OS, Bauer S, Hartmann JT, Schöffski P, Christensen TB, Pink D, Daugaard S, Marreaud S, Van Glabbeke M, Blay JY. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2007; 43:1017-22. [PMID: 17336054 DOI: 10.1016/j.ejca.2007.01.014] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2007] [Accepted: 01/15/2007] [Indexed: 11/15/2022]
Abstract
No standard treatment is established for patients with advanced soft tissue sarcoma after previous chemotherapy with anthracyclines and ifosfamide, given either in combination or sequentially. Exatecan (DX-8951f) is a totally synthetic analogue of the topoisomerase I-inhibitor camptothecin, which was synthesised to impart increased aqueous solubility, greater tumour efficacy, and less toxicity than camptothecin itself, topotecan or irinotecan. Since some activity against soft tissue sarcomas, especially leiomyosarcomas, has been reported for topoisomerase I-inhibitors, a study with a new and more potent agent seemed justified. We report on a prospective multicentre phase II study of Exatecan in adult soft tissue sarcomas failing 1 or 2 lines of chemotherapy in advanced phase, performed within the STBSG of EORTC. Thirty-nine patients (16 leiomyosarcomas and 23 other histologies) were included in two independent strata and received a total of 141 cycles (median 2). Median age was 61 years, range 25-76. Exatecan was given as i.v. infusion over 30 min at a dose of 0.5mg/m2 every day for five consecutive days, repeated every 21 days. Seventy-four percentage of cycles could be given without dose or schedule modification. The main toxicity was haematotoxicity with grade 3/4 neutropenia in 49%, grade 3/4 thrombocytopenia in 23%, and grade 3/4 anaemia in 15% of patients, respectively. Non-haematological toxicity consisted mainly of grade 2/3 dyspnoea in 36% of patients and grade 2/3 fatigue in 28%. One treatment-related toxic death due to septic shock was reported. Best overall response was no change with 60% in the leiomyosarcoma group and 53% in the non-leiomysarcoma group, respectively. The 3 months progression-free survival estimates are 56% for leiomysarcomas and 26% for other histologies, respectively. Using a two-step statistical design, the trial was stopped after the first step in both strata, due to lack of activity. In pretreated soft tissue sarcoma patients, Exatecan is well tolerated but does not achieve any objective responses. However, with respect to progression-free survival, Exatecan did show some activity in leiomyosarcomas.
Collapse
Affiliation(s)
- P Reichardt
- Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Robert-Rössle-Klinik, HELIOS-Klinikum Berlin-Buch, Charité Campus Buch, Lindenberger Weg 80, 13125 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Van Herpen C, Fiedler W, Toma S, Marreaud S, Van Laarhoven H, Lasch P, Bogaerts J, Heerschap A, Bordignon C, Punt C. 366 POSTER Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041). EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70371-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
40
|
Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, Marreaud S, van Glabbeke M, Blay J, Judson I. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer 2006; 42:2303-9. [PMID: 16891112 DOI: 10.1016/j.ejca.2006.04.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2006] [Accepted: 04/07/2006] [Indexed: 10/24/2022]
Abstract
This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas. Five dose levels (L) were studied: Caelyx 30 mg/m2 (L1-4) or 40 mg/m2 (L5) 1-h infusion d 1 q 3 weeks + ifosfamide and mesna at X g/m2/4 h d 1-3 q 3 weeks at five doses: L1: X = 1.7 g; L2: X = 2 g; L3: X = 2.5 g; L4 and L5: X = 3 g. Cohorts of 3 patients were entered at each level unless a dose-limiting toxicity (DLT) occurred. In case of DLT in 1 of 3 patients a new cohort was added. Toxicity was evaluated by Common Toxicity Criteria (CTC). A total of 28 patients was included: 4 at dose L1, 8 at L2, 3 at L3, 6 at L4, and 7 at L5. Median age was 60 years (range 29-69 years). Male/female ratio was 12/16. Seventy-five percent of patients had a performance status of 1.0 and 36% had leiomyosarcomas. No DLT was observed at dose L1-4. Six patients developed a DLT at dose L5, and thus the recommended dose is level 4 (i.e. Caelyx 30 mg/m2/1 h d 1+ifosfamide at 3 g/m2/4 h d 1-3 q 3 weeks). Few haematological and biochemical events were observed and the principal toxicities were granulocytopaenia and leucopaenia. Five patients discontinued therapy because of toxicity, 4 of them at dose level 5. Non-haematological toxicities > grade 2 were also few. Palmar-plantar erythrodysesthesia (PPE) > grade 1 was not seen. Two patients obtained partial response (PR) and 13 stable disease (SD). Median overall survival (OS) was 333 d and median progression-free survival (PFS) 174 d. In conclusion, this seems to be a feasible combination in patients with advanced soft tissue sarcomas, allowing ifosfamide to be given in a dosage similar to that used when given alone. The recommended dose for future studies is Caelyx 30 mg/m2/1 h d 1+ifosfamide 3 g/m2/4 h d 1-3 q 3 weeks.
Collapse
Affiliation(s)
- O S Nielsen
- Aarhus University Hospital, Department of Oncology, Nörrebrogade 44, DK-8000 Aarhus C, Denmark.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Coudert B, Focan C, Genet D, Giacchetti S, Lentz M, Marreaud S, Baron B, Gorlia T, Lévi F. Optimal circadian time of vinorelbine (V) combined with chronomodulated 5-FU in pretreated metastatic breast cancer patients. EORTC 05971 randomized multicenter study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2066 Background: Chronotherapy is an aim to increase efficacy/toxicity ratio. Objectives: to define the dosing least toxic time (DLTT) of V (30 mg/m2/d at D1 and D6), combined with chrono 5-FU (10 pm-10 am) (850 mg/m2 D2-D5) over 3 courses q3w. Methods: A logistic regression model (LRM) estimated the DLTT assuming a sinusoidal distribution over time (i.e. over the 8 different arms) of the toxicity rate observed in each arm. The associated 90% confidence limits (CL) has been obtained by bootstrap method. Results: 90 patients were recruited. Toxicity in 46 pts led to the V dosage reduction to 25 mg/m2/d. 40 and 43 pts were assigned the V30 and the V25 regimen. 12% pts went off for toxicity, 5% for PD, 1% for refusal, 1% for unrelated death. 224 cycles were analyzed . V and 5FU relative dose intensities were 79.4% and 78.2% in the V30 while 88.1% and 87.4% in the V25 pts. Over the 3 cycles, toxicity by cycle was: Grade (G) 3 and G4 leucopenia in 47% and 29%, G3 and G4 neutropenia in 12% and 77%. G3 febrile neutropenia in 34%. G2 thrombopenia and anemia in 4% each. Other G3 and G 4 toxicity were stomatitis (12%), alopecia (7%), and less than 5%: cardiovascular, lethargy, diarrhea, constipation, other gastrointestinal, infection, sensory, pulmonary. LRM could not demonstrate a DLTT for the neutropenia G3–4 incidence, the primary endpoint. However, based on the stratified by dose analysis, a 90% CI of less than 6 hours width was observed: - around 17H17 [14H04–20H03] for the incidence of leucopenia G3–4. - around 8H16 [06H04–10H39] for tolerability (dose reduction, dose delay or treatment interruption for toxicity reason). This suggests that treatment tolerability was influenced by other factors beside leucopenia nadir. No other 90% CI of less than 6 hours width could be observed for other toxicity endpoints. Conclusions: Using a novel time finding study design with ad hoc statistics, this first randomized multicenter study has determined a DLTT for Vinorelbine in 90 women with MBC. Additional studies are ongoing to further assess the relevance of this trial design method that could prove useful for improving the safety of anticancer drugs during their clinical development. Support Pierre Fabre Oncology, Ligue Bourguignonne contre le Cancer No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Coudert
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - C. Focan
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - D. Genet
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - S. Giacchetti
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - M. Lentz
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - S. Marreaud
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - B. Baron
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - T. Gorlia
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - F. Lévi
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| |
Collapse
|
42
|
Blay J, Le Cesne A, Whelan J, Van Oosterom A, Ray-Coquard I, Judson L, Hogendorn P, Marreaud S, Hermans C, Van Glabbeke M. Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9517] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9517 Background: Synovial sarcomas (SyS) have been reported to overexpress HER1 in gene expression profile experiments and immunohistochemistry. Gefitinib, a specific inhibitor of HER1, was therefore tested in advanced or metastatic SyS failing doxorubicin (Doxo) ± ifosfamide (Ifo). Methods: Patients (pts) with advanced or metastatic SyS expressing HER1 using IHC were included. The principal inclusion criterias were: disease not curable with surgery and/or radiation, presence of a measurable progressive lesion(s), pretreatment with 1–3 line of chemotherapy in metastatic phase, ECOG PS 0 to 2, age ≥18 years. Gefitinib was given at 500mg/day until progression or intolerance. Primary endpoint was the rate of progression free survival at 3 months. A two step Simon design was used with a p0 of 25% and a p1 of 45%, with α and β of 0.1. 44 patients were scheduled to be recruited. Results: Between 10/02 and 10/05, 48 pts were included in 12 EORTC STBSG centers, 27 (56%) males and 21 (44%) females. Median age was 42 years (range 19–66). Metastatic sites were lung in 92% and soft tissue or lymph nodes in 42%, of the patients. Respectively 42, 40 and 18% of the patients had received 1, 2 and >2 lines of CT. As of December 2005, 37 pts are evaluable for toxicity and 39 for the primary endpoint. Median treatment duration was 11 weeks (range 2–25). Toxicity (G1–4) reported included fatigue (43%), diarrhea (54%), cough (35%), dyspnea (43%), cutaneous (73%). G3–4 toxicities were dyspnea (9), fatigue (4), cutaneous (2), cough (1), neurological (2), thombosis (2), hypoxia (1), infection (1). There was no drug related death. No dose reduction has been reported so far, but treatment had to be temporarily interrupted in 23% of the patients. As of December 2005, there were no objective response reported. Seven (18%) pts achieved stable disease as best response. At 3 months, 5 of the 39 (13%) evaluable patients achieved PFS; 6 and 12 months PFS were 10% and 3% respectively. Conclusions: 13% of SyS expressing HER1 achieved prolonged progression free survival at least 12 weeks) with gefitinib. Gene expression profiling and protein expression were not accurate predictors of gefitinib activity in this model. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Blay
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - A. Le Cesne
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - J. Whelan
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - A. Van Oosterom
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - I. Ray-Coquard
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - L. Judson
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - P. Hogendorn
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - S. Marreaud
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - C. Hermans
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| | - M. Van Glabbeke
- U590, Lyon, France; Institut Gustave Roussy, Villejuif, France; University College London Hospital, London, United Kingdom; UZ Gasthuisberg, Leuven, Belgium; Royal Marsden Hospital, London, United Kingdom; University of Leiden, Leiden, The Netherlands; EORTC Data Center, Brussels, Belgium
| |
Collapse
|
43
|
Innominato PF, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Mormont MC, Waterhouse J, Gorlia T, Marreaud S, Lévi FA. Quality of life (QoL) correlates with the rest/activity circadian rhythm (RAR) in patients (pts) with metastatic colorectal cancer (MCC) on first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: An international multicenter study (EORTC 05963). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. F. Innominato
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - C. Focan
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - G. A. Bjarnason
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - C. Garufi
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - S. Iacobelli
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - M. C. Mormont
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - J. Waterhouse
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - T. Gorlia
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - S. Marreaud
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| | - F. A. Lévi
- G. D’Annunzio Univ, Chieti, Italy; Les Clin Saint-Joseph, Liège, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Regina Elena Cancer Institute, Roma, Italy; G. D’Anunnzio Univ, Chieti, Italy; INSERM, Villejuif, France; Univ of Manchester, Manchester, United Kingdom; EORTC Data Ctr, Brussels, Belgium; Paul-Brousse Hosp, INSERM, Univ Paris XI, Villejuif, France
| |
Collapse
|
44
|
Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 2005; 15:1816-24. [PMID: 15550588 DOI: 10.1093/annonc/mdh469] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Aviscumine is an Escherichia coli-derived recombinant type II ribosome-inactivating protein with potent antitumor activity in vitro and in vivo. It is the recombinant counterpart of natural mistletoe lectin-I. The current study was performed to determine the safety profile, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the intravenous (i.v.) administration of aviscumine in cancer patients. Translational research included the evaluation of pharmacokinetics and monitoring of plasma cytokine and anti-aviscumine antibody induction after administration of the drug. PATIENTS AND METHODS Aviscumine was given twice weekly as a 1 h central i.v. infusion in patients with advanced, refractory progressive, solid malignant tumors who had not been previously exposed to natural mistletoe preparations. They had histologically or cytologically verified disease, were > or =18 years old, had an Eastern Cooperative Oncology Group performance status < or =2 and adequate bone marrow, liver and renal function. DLT was defined as any non-hematological grade 3-4 toxicity (National Cancer Institute Common Toxicity Criteria version 2.0), neutrophil count <500/microl for > or =7 days, febrile neutropenia or thrombocytopenia grade 4. The MTD was defined as the dose at which >20% of patients experienced DLT during the first treatment cycle. The Continual Reassessment Method was used to determine the number of patients required per dose level. RESULTS Forty-one fully eligible patients (19 male, 22 female) with a median age of 56 years (range 37-74) were enrolled. Colorectal, ovarian, renal cell and breast cancer were the most common tumor types. Dose levels of aviscumine ranged from 10 to 6400 ng/kg. The median number of cycles was two (range one to eight). Common clinical toxicities in cycle 1 were fatigue, fever, nausea, vomiting and allergic reactions. Fatigue grade 3 was dose limiting in one of six patients at 4000 ng/kg and reversible grade 3 liver toxicity (elevation in alkaline phosphatase, transaminases and/or gamma-glutamyltransferase) occurred in one of 10 patients at 4800 ng/kg and in two of five patients at 6400 ng/kg. The best response (RECIST criteria) was stable disease in 11 patients, lasting for two to eight cycles. The pharmacokinetic evaluation revealed a short alpha half-life of 13 min and linear kinetics on dose levels > or =1600 ng/kg. Aviscumine stimulated the immune system with a release of cytokines such as interleukin (IL)-1beta, IL-6 and interferon-gamma, and induced immunoglobulin (Ig) G- and/or IgM-anti-aviscumine antibodies of uncertain clinical relevance. CONCLUSIONS The recommended dose for further clinical trials is 5600 ng/kg twice weekly. Based on the short half-life of the recombinant protein observed in this trial, the exploration of prolonged infusion schedules of aviscumine is warranted.
Collapse
MESH Headings
- Adjuvants, Immunologic/administration & dosage
- Adjuvants, Immunologic/adverse effects
- Adjuvants, Immunologic/pharmacokinetics
- Adjuvants, Immunologic/therapeutic use
- Adult
- Aged
- Female
- Half-Life
- Humans
- Immune System/drug effects
- Infusions, Intravenous
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasms/drug therapy
- Plant Preparations/administration & dosage
- Plant Preparations/adverse effects
- Plant Preparations/pharmacokinetics
- Plant Preparations/therapeutic use
- Plant Proteins/administration & dosage
- Plant Proteins/adverse effects
- Plant Proteins/pharmacokinetics
- Plant Proteins/therapeutic use
- Ribosome Inactivating Proteins, Type 2
- Toxins, Biological/administration & dosage
- Toxins, Biological/adverse effects
- Toxins, Biological/pharmacokinetics
- Toxins, Biological/therapeutic use
- Treatment Outcome
Collapse
Affiliation(s)
- P Schöffski
- Department of Haematology and Oncology, Hannover Medical School, Hannover, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|